Multinational observational cohort study of covid-19-associated pulmonary aspergillosis1

Nico A.F. Janssen, Rémy Nyga, Lore Vanderbeke, Cato Jacobs, Mehmet Ergün, Jochem B. Buil, Karin Van Dijk, Josje Altenburg, Catherine S.C. Bouman, Hans I. Van der Spoel, Bart J.A. Rijnders, Albert Dunbar, Jeroen A. Schouten, Katrien Lagrou, Marc Bourgeois, Marijke Reynders, Niels Van Regenmortel, Lynn Rutsaert, Piet Lormans, Simon FeysYves Debavaye, Fabienne Tamion, Damien Costa, Julien Maizel, Hervé Dupont, Taieb Chouaki, Saad Nseir, Boualem Sendid, Roger J.M. Brüggemann, Frank L. Van de Veerdonk, Joost Wauters, Paul E. Verweij*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

22 Citations (Scopus)
2 Downloads (Pure)

Abstract

We performed an observational study to investigate intensive care unit incidence, risk factors, and outcomes of coronavirus disease-associated pulmonary aspergillosis (CAPA). We found 10%-15% CAPA incidence among 823 patients in 2 cohorts. Several factors were independently associated with CAPA in 1 cohort and mortality rates were 43%-52%.

Original languageEnglish
Pages (from-to)2892-2898
Number of pages7
JournalEmerging Infectious Diseases
Volume27
Issue number11
DOIs
Publication statusPublished - Nov 2021

Bibliographical note

Acknowledgments:
We sincerely thank all the patients included in this study.
We thank all colleagues in the participating centers for
submitting their data. We thank Maeve van den Aakster,
Burak Atasever, Aleid Breuning, Elena Decat, Joke Denolf,
Ruben De Rouck, Laura De Velder, Willemijn van
der Kleij, Gideon Saelman, Evi Smeyers, Manon
Vanbellinghen, and Lauren Van der Sloten for their
support in data entry.
L.V. reports grants from the Research Foundation Flanders
during the study period and nonfinancial support from
Gilead Sciences and Pfizer for work outside the submitted
study. J.B.B. reports grants from F2G, Gilead Sciences, and
Thermo Fisher Scientific for work outside the submitted
study. B.J.A.R. reports grants from Gilead Sciences for
work outside the submitted study. K.L. reports
nonfinancial support from Pfizer and personal fees from
SMB Laboratoires, Gilead Sciences, FUJIFILM Wako,
Thermo Fisher Scientific, and MSD for work outside the
submitted study. S.N. reports personal fees from MSD,
Pfizer, Gilead, bioMérieux, and Bio-Rad for work outside
the submitted study. K.L. received consultancy fees from
MSD, SMB Laboratoires Brussels, and Gilead; nonfinancial
support from Pfizer and MSD, speaker fees from Gilead
Sciences, FUJIFILM WAKO, and Pfizer; and a grant from
Thermo Fisher Scientific, for work outside the submitted study. R.J.M.B. has served as a consultant to Astellas
Pharma, Inc., F2G, Amplyx, Gilead Sciences, Merck Sharp
& Dohme Corp., Mundipharma, and Pfizer, Inc., and has
received unrestricted and research grants from Astellas
Pharma, Inc., Gilead Sciences, Merck Sharp & Dohme
Corp., and Pfizer, Inc., for work outside the submitted
study; all contracts were through Radboudumc, and all
payments were invoiced by Radboudumc. J.W. reports
grants from Gilead during the study period, grants and
nonfinancial support from MSD, and grants from Pfizer for
work outside the submitted study. P.E.V. reports grants
from Mundipharma, F2G, Pfizer, Thermofisher,
Gilead Sciences, and Cidara and nonfinancial support from
IMMY for work outside the submitted study.
F.L.v.d.V. is supported by a Vidi grant of the Netherlands
Association for Scientific Research.

Publisher Copyright: © 2021 Centers for Disease Control and Prevention (CDC). All rights reserved.

Fingerprint

Dive into the research topics of 'Multinational observational cohort study of covid-19-associated pulmonary aspergillosis1'. Together they form a unique fingerprint.

Cite this